Cancer NetworkOriginal article
<![CDATA[Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM]]>
Data ReadoutpositiveramantamigPositive
AI Analysis
Summary
Ramantamig demonstrated impressive rates of MRD negativity in relapsed/refractory multiple myeloma, according to clinical commentary from Dr. Jeffrey V. Matous highlighting the clinical significance of these results.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Achieved impressive rates of MRD negativity in relapsed/refractory myeloma
Importance:6/10
Sentiment:
0.75
multiple myelomaMRD negativityrelapsed/refractoryclinical data
Read the original article
Published by Cancer Network on October 9, 2026 6:00 PM